- Statement of Changes in Beneficial Ownership (4)
07 4월 2011 - 1:14AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Expires:
February 28, 2011
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
BERTOLINI ROBERT J
|
2. Issuer Name
and
Ticker or Trading Symbol
GENZYME CORP
[
GENZ
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
_____ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
500 KENDALL STREET
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
4/4/2011
|
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Genzyme common stock (GENZ)
|
4/4/2011
|
|
M
|
|
2375.0000
(1)
|
A
|
$0.0000
|
4750.0000
|
D
|
|
Genzyme common stock (GENZ)
|
4/4/2011
|
|
D
|
|
2375.0000
|
D
|
$74.0000
|
2375.0000
|
D
|
|
Genzyme common stock (GENZ)
|
4/4/2011
|
|
U
|
|
2375.0000
|
D
|
$74.0000
|
0.0000
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Restricted Stock Units
|
$0.0000
|
4/4/2011
|
|
M
|
|
|
2375.0000
|
(1)
|
(1)
|
Genzyme common stock (GENZ)
|
2375.0000
|
$0.0000
|
0.0000
|
D
|
|
Stock Option (right to buy)
|
$51.5200
|
4/4/2011
|
|
D
|
|
|
7125.0000
|
(2)
|
6/16/2020
|
Genzyme common stock (GENZ)
|
7125.0000
|
$51.5200
|
0.0000
|
D
|
|
Stock Option (right to buy)
|
$49.4200
|
4/4/2011
|
|
D
|
|
|
7125.0000
|
5/20/2010
(2)
|
12/8/2019
|
Genzyme common stock (GENZ)
|
7125.0000
|
$49.4200
|
0.0000
|
D
|
|
Explanation of Responses:
|
(
1)
|
The vested restricted stock units were scheduled to vest on the date of the 2011 annual meeting of shareholders.
|
(
2)
|
This option, which provided for vesting at the next annual meeting of shareholders, was cancelled upon the consummation of the sanofi-aventis tender offer in exchange for a payment representing (A) an amount of cash equal to the excess of $74.00 over the exercise price of the option, multiplied by the total number of shares subject to such options, and (B) one contingent value right (CVR) per cancelled option.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
BERTOLINI ROBERT J
500 KENDALL STREET
CAMBRIDGE, MA 02142
|
X
|
|
|
|
Signatures
|
Susan P. Cogswell, Attorney-in-Fact
|
|
4/6/2011
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Genzyme (NASDAQ:GENZ)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Genzyme (NASDAQ:GENZ)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
Genzyme Corp. - Genzyme Corp. Common Stock (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More News Articles